

Supplementary material

IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases

Divya Thiagarajan¹, Nina Oparina¹, Susanna Lundström², Roman Zubarev², Jitong Sun¹, the PRECISESADS Clinical Consortium³, Marta Alarcon-Riquelme^{1,3} and Johan Frostegard^{1*}

¹Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

²Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

³GENYO, Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Government, Parque tecnolygico de la salud, 18016, Granada, Spain

Supplementary table 1. Cross-disease comparison of anti-PC and anti-MDA IgM levels

A. FDR-corrected p-values of pairwise comparisons: Mann-Whitney

MDA_IgM	Control	MCTD	PAPs	RA	SjS	SLE	SSc	UCTD
Control		0.174	0.004	0.004	0.306	0.639	0.042	0.174
MCTD	0.174		0.004	0.008	0.455	0.163	0.027	0.053
PAPs	0.004	0.004		0.095	0.002	0.008	0.042	0.055
RA	0.004	0.008	0.095		0.002	0.027	0.412	0.455
SjS	0.306	0.455	0.002	0.002		0.174	0.008	0.058
SLE	0.639	0.163	0.008	0.027	0.174		0.164	0.306
SSc	0.042	0.027	0.042	0.412	0.008	0.164		0.874
UCTD	0.174	0.053	0.055	0.455	0.058	0.306	0.874	

PC_IgM	Control	MCTD	PAPs	RA	SjS	SLE	SSc	UCTD
Control		0.006	0.024	~.0001	0.001	0.002	0.806	0.327
MCTD	0.006		0.001	<.0001	0.350	0.266	0.006	0.087
PAPs	0.024	0.001		0.806	0.001	0.001	0.047	0.021
RA	~.0001	<.0001	0.806		<.0001	<.0001	0.001	0.001
SjS	0.001	0.350	0.001	<.0001		0.586	0.001	0.177
SLE	0.002	0.266	0.001	<.0001	0.586		0.003	0.342
SSc	0.806	0.006	0.047	0.001	0.001	0.003		0.299
UCTD	0.327	0.087	0.021	0.001	0.177	0.342	0.299	

B. FDR-corrected p-values of pairwise comparisons: two-tailed t-test

MDA_IgM	Control	MCTD	PAPs	RA	SjS	SLE	SSc	UCTD
Control		0.169	0.006	0.002	0.508	0.290	0.020	0.025
MCTD	0.169		0.002	0.002	0.317	0.055	0.011	0.017
PAPs	0.006	0.002		0.091	0.004	0.014	0.035	0.097
RA	0.002	0.002	0.091		<.0001	0.035	0.317	0.850
SjS	0.508	0.317	0.004	<.0001		0.135	0.011	0.035
SLE	0.290	0.055	0.014	0.035	0.135		0.239	0.228
SSc	0.020	0.011	0.035	0.317	0.011	0.239		0.618
UCTD	0.025	0.017	0.097	0.850	0.035	0.228	0.618	

PC_IgM	Control	MCTD	PAPs	RA	SjS	SLE	SSc	UCTD
Control		0.004	0.024	<.0001	0.006	0.003	0.001	0.027
MCTD	0.004		0.002	<.0001	0.474	0.474	0.022	0.117
PAPs	0.024	0.002		0.474	0.002	0.002	0.037	0.002
RA	<.0001	<.0001	0.474		<.0001	<.0001	<.0001	0.002
SjS	0.006	0.474	0.002	<.0001		0.997	0.005	0.172
SLE	0.003	0.474	0.002	<.0001	0.997		0.003	0.165
SSc	0.001	0.022	0.037	<.0001	0.005	0.003		0.552
UCTD	0.027	0.117	0.002	0.002	0.172	0.165	0.552	

p<0.05

Color scheme: p<0.005

Supplementary Table 2. The most prominent differences between anti-PC and anti-PC-FT as well as anti-MDA and anti-MDA-FT, respectively. Numbers are reported as log(ppm) of the relative peptide distribution in respective sample. CDR peptide sequence regions are bolded. Peptides with a ppm <1, were set as 0. – peptide was not detected. p<0.05 (significant) are marked out.

Type	Region	Sequence	anti-PC	anti-PC-	anti-	anti-MDA-	p-values -anti PC vs		
				FT	MDA	FT	anti-PC- FT	anti- MDA	anti- MDA-FT
HV	CDR3	EESFWGQGTLVTVSSASTK	2.4±0.1	0.3±0.3	-	-	1.4E-05	-	-
		ENDNKFSFDYWGQGTLVTVSSASTK	3.1±0.2	0.5±0.5	1.2±1.1	-	1.1E-04	8.8E-02	-
		FSFDYWGQGTLVTVSSASTK	3.9±0.1	1.6±0.4	3.2±0.2	0.2±0.2	1.7E-05	2.1E-03	7.9E-07
	CDR2	GLEWLGYVYYSGVTR	1.5±1.1	0.1±0.3	-	-	7.6E-02	-	-
		GLEWVAVVSSDGR	2.3±0.3	0.1±0.1	-	-	3.5E-06	-	-
		GLEWVSSLNSDSK	1.6±0.5	-	-	-	-	-	-
	FR3	GLEWVSSMSASDGGBTYYADSVK	1.8±1.3	0.4±0.3	-	0.6±0.6	7.7E-02	-	1.9E-01
		NTLYLQMNSLTTEDTALYYCAK	3.3±0.2	1.1±0.2	2.6±0.1	0.0±0.0	1.2E-05	4.7E-03	9.3E-05
		ASTLQSGVPSR	4.5±0.2	2.0±0.2	4.5±0.2	1.7±0.2	5.3E-06	8.0E-01	1.2E-05
	KV	LLLYAASTLQSGVPSR	2.7±0.2	2.4±0.1	2.7±0.4	2.2±0.3	4.6E-02	9.0E-01	4.0E-02
		ELTQSPATLSLSPGER	1.1±0.8	-	-	-	-	-	-
		VTLSCSGSSANLGK	2.2±0.3	-	-	-	-	-	-
LV	CDR1	NYVSWYQQLPGTAPK	2.0±0.6	1.3±0.1	-	1.3±0.1	8.9E-02	-	9.2E-02
		LLLYGNNERPSGLPDR	2.0±0.8	0.1±0.3	-	0.3±0.5	4.5E-03	-	7.6E-03

Supplement Figure 1. Low levels of anti-PC and anti-MDA IgMs across systemic rheumatic diseases and in healthy controls

For each subset % of samples with the IgM level lower than overall 25th or 10th percentile is shown.



